AF
MRNS

Amalgamated Financial’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Amalgamated Financial’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$56K Buy
+6,013
New +$59.7K ﹤0.01% 2381

Other funds holding MRNS

LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Amalgamated Financial's MRNS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Marinus Pharmaceuticals, Inc (MRNS) in Q1 2022: 6,013 shares worth $56K. The stake represents ﹤0.01% of the portfolio and ranks #2381 among its holdings.

83 funds tracked by Wall St. Rank hold MRNS as of Q1 2022.

  • Amalgamated Financial held 6,013 shares of Marinus Pharmaceuticals, Inc worth $56K as of Q1 2022.
  • Marinus Pharmaceuticals, Inc was a new Amalgamated Financial position in Q1 2022.
  • Marinus Pharmaceuticals, Inc made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2381 holding.
  • 83 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.